An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels
Eppie M Yiu, Geneieve Tai, Roger E Peverill, Katherine J Lee, Kevin D Croft, Trevor A Mori, Barbara Scheiber-Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P Vogel, Gary Rance, Sarah EM Stephenson, Joseph P Sarsero, Creina Stockley, Chung-Yung J Lee, Andrew Churchyard, Marguerite V Evans-Galea, Monique M Ryan, Paul J Lockhart, Louise A Corben Show all
JOURNAL OF NEUROLOGY | SPRINGER HEIDELBERG | Published : 2015
Related Projects (2)
This study was funded by the Kyle Bryant Translational Research Award, Friedreich Ataxia Research Alliance (USA). The authors gratefully acknowledge the participants of this study. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.